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A B S T R A C T
A set of 1,8-naphtalimides derivatives were synthesized and tested against three protozoans that cause important
human diseases: Leishmaniainfantum, Trypanosomabrucei and Trypanosomacruzi. Additionally, toxicity was
determined by growth inhibition of THP-1 derived macrophages. The results suggest that chemical modifications
in the carbon chain linking the naphthalimide and the substituting groups have different effects in the parasites.
This work should provide new insights for the design and optimization of more potent and directed
naphthalimide derivatives against these organisms.
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1. Introduction
Parasitic diseases caused by trypanosomatids are still an
important health problem, mainly in tropical and
subtropical areas. In addition, temperate regions of our
globe, including North America and the Asia-Pacific region
are also affected by disease-causing protozoans like
Leishmania spp.,Trypanosomacruzi and Trypanoso-
mabrucei. These are the species of trypanosomatids most
associated with human health, being responsible for high
mortality and morbidity[1]. There are still no vaccines and
the actual chemotherapies are far from satisfactory, owing
to the emergence of resistances, serious side effects, and its
limited efficacy. Therefore, it is imperative to continue the
discovery of new drugsto treat these diseases[2].
2. Experimemtal
Naphthalimides and bis-naphthalimidesare classes of
compounds bearing aromatic groups that have generated
intense interest by scientists around the world because of
their many reported biological activities. Special attention
has been devoted to the high anticancer activity of
naphthalimides, which is due to their interactions with
DNA by a mechanism of intercalation[3–5]. In addition,
recent studies showed that 1,8-naphthalimide derivatives
also demonstrated other biological activities, such as
antitrypanosomal[6]. In this context, this work proposes to
study the relationship between the structure and the activity
of a set of 1,8-naphtalimide derivatives with 2, 3 or 4
carbons linking the naphthalimide moiety to different
functional groups (amine, imine, guanidine, urea, amide,
and 1,2,3-triazole) against three trypanosomatids:
Leishmaniainfantum, Trypanosomabrucei and Trypano-
somacruzi. These 1,8-naphtalimide derivatives compounds
had been recently synthesized and include
naphthalimidoalkylamines1a,b, and its heterocyclic imine
derivatives 2a-l, heterocyclic amine derivatives 3f,g,
guanidine derivatives 4a-c, urea derivatives 5a-l, amide
derivatives 6a-l and triazol derivatives 7d-f[7,8].
Figure 1: Naphthamides compounds 1a,b, 2a-l, 3f,g, 4a-c, 5a-l, 6a-l, 7d-f used in trypanosomatids tests: Leishmaniainfantum,
Trypanosomabrucei, and Trypanosomacruzi.
3. Results and Discussion
All the naphthalimides compounds stock solutions were
prepared in DMSO in a concentration of 10 mM and stored at
-20 °C. Anti T. cruzi(Y strain) activity was performed by
high content screening (adapted from[9]); for T. brucei(L427
Wild Type)bloodstream forms and axenic amastigote of L.
infantum(clone MHOM/MA671TMA-P263)activity was
determined using the resazurin-based assay[10,11];
intracellular amastigoteactivity of L. infantum was performed
by luciferase assay (adapted from[12]).The cellular toxicity
of the compounds was evaluated on THP-1 differentiated
macrophages using the MTT assay[13].The tablesummarizes
the results obtained for the compounds with relevant anti-
parasitic activityat 10 μM concentration. Overall, our results
showthat the best activity was against T.brucei. The group
ofnaphthalimidoalkylamines represented by compound1a
and1b show strong inhibition at concentration 10μM
(101±1% inhibition); however compound 1apresentshigher
toxicity withNOAEL (no observed adverse effect level)> 25
μM in comparison with 1b NOAEL > 100μM, suggesting
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that shorter a carbon chain (n = 2) increasesthe
cytotoxicity.The group of heterocyclic iminescompounds 2a-
l generally reveals good activity against T.brucei.Within
theimino furan subgroup,compounds 2b, 2f and 2j, only 2f
with 3 carbon atoms chain showsto be active (101 ± 1%
inhibition), andin the subgroup incorporating imidazole (2d,
2h and 2l)compound 2l,with 4 carbon atoms chain, is the
least active. The toxicity for heterocyclic imines is lower
with 3 and 4 carbon chains. The compound with the best
balance activity-toxicity belongs to compound 2e, with a
three-carbon atom chain and a pyrrole unit. Heterocyclic
aminescompoundsare also active against T. brucei,our results
showing almost complete inhibition with compound 3f (99 ±
1% inhibition) and 3g (96 ± 3% inhibition).
However,compound3g showslower cytotoxicity than 3f, with
NOAEL > 50μM and > 25μM, respectively.Guanidine
substituted compounds 4a-calso reveal some anti-T.brucei
activity, with a clear tendency for toxicity to decrease with
the increase of the carbon chain length.Within the urea-
substituted compounds 5a-l the most active compounds
against T.brucei, at the concentrations tested, is 5fand 5l
bothwith 4 carbon atom chains. Within this group, when the
carbon chain increases up to four carbon atoms, so does the
activity increase.Also the nature of the terminal groups in
compounds 5a-lis also found to be important for activity.
Comparing the cytotoxicity of the four carbon chain
members in this group (5c, 5f, 5i and 5l), only compound
5cwas found non toxic, suggesting that un-
substitutedureasare less toxic than substituted ureasagainst
THP-1 cell line. In relation to the triazole group, only
compound 7f shows activity against T. brucei (90 ± 3%
inhibition), with toxicity increasing when the triazole group
is linked by a 3 carbon atoms chain.Regarding T. cruzi,
amine 1aand guanidine 4ashows modest anti-parasitic
activity (34 ± 9 % inhibition and 45 ± 9% inhibition,
respectively). Urea 5l bearing a 4 carbon atoms chain and a
n-butyl group as substituent shows to be the most active
compound of all tested against T. cruzi, (81 ± 8 % inhibition).
However, allcompounds that show some activity against T.
cruziare accompanied by an increase in cytotoxicity,
suggesting a nonspecific mechanism. Previous studies
conducted in our laboratory have shown that bis-
naphthalimidopropyl (BNIP) derivatives compounds exert
significant effects against L.infantum[14].
Surprisingly, no significant anti-leishmanial activity was
found for all the groups studied; either
againstL.infantumintracellular and axenic amastigotes. A
hypothesis is that the activity is dependent on a second
naphthilimide group in the molecule. Overall, the toxicity of
the synthesized compounds with a 2 carbon atoms linker
presents the higher toxicity.An exception was observed with
the substituted urea-derived group, wherethe 4 carbon atoms
chain compounds are the most toxic, with the exception urea
5c. The group of amides 6a-l compounds doesnot present
relevantanti-parasitic activity (data not shown). In
conclusion,naphthalimides bearing primary alkylamines and
un-substituted ureas are the hits for further research in
Trypanosome brucei, in combination with longer linkers, and
O-, N-functionalized linkers. No interesting results have been
found to the other two trypanosomatids studied.
Table:Anti-parasitic activity against Leishmaniainfantum intracellular amastigotes and axenic amastigotes,
Trypanosomabrucei, Trypanosomacruziand cytotoxicity in THP1-derived macrophages for the compounds tested.
Functional groups:
naphthalimidoalkylamines 10μM single dose testing (%activity ± SD) Toxicity
NOAEL
(μM)Compound Radical / Number
of carbons
Leishmania
infantum
intracellular
amastigotes
Leishmania
infantum
axenic
amastigotes
Trypanosoma
brucei
Trypanosoma
cruzi
1a R=NH2 / n=2 23 ± 17 5 ± 5 101 ± 1 34 ± 9 > 25
1b R=NH2 / n=3 N. A. N. A. 101 ± 1 N. A. > 100
Functional group:
Heterocyclic imine
2a X=NH/Y=C/ n=2 N. A. 9 ± 7 101 ± 2 22 ± 13 > 25
2b X=O/ Y=C/ n=2 N. A. 5 ± 0 17 ± 12 N. A. > 25
2c X=S/Y=C/ n=2 N. A. 1 ± 3 8 ± 5 N. A. > 25
2d X=NH/Y=N/ n=2 N. A. 2 ± 1 101 ± 1 25 ± 4 > 25
2e X=NH/Y=C/ n=3 N. A. N. A. 101 ± 1 N. A. > 100
2f X=O/Y=C/ n=3 N. A. 20 ± 21 101 ± 1 N. A. > 50
2g X=S/Y=C/ n=3 N. A. N. A. 101 ± 1 N. A. > 50
2h X=NH/Y=N/n=3 6 ± 13 23 ± 16 99 ± 2 N. A. > 50
2i X=NH/Y=C/ n=4 4 ± 12 1 ± 12 53 ± 5 N. A. > 50
2j X=O/Y=C/ n=4 N. A. 19 ± 4 26 ± 10 N. A. > 50
2k X=S/Y=C/ n=4 N. A. 27 ± 3 94 ± 2 N. A. > 50
2l X=NH/Y=N/ n=4 N. A. 24 ± 12 24 ± 3 N. A. > 100
Functional group:
Heterocyclic amine
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3f X=O/Y=C/N=3 N. A. 13 ± 1 99 ± 1 17 ± 15 > 25
3g X=S/ Y=C/N=3 N. A. 9 ± 4 96 ± 3 25 ± 10 > 50
Functional group:
Guanidine
4a R=H/ n=2 N. A. 4 ± 10 100 ± 1 45 ± 9 > 25
4b R=H/ n=3 N. A. 22 ± 8 101 ± 1 N. A. > 50
4c R=H/ n=4 N. A. 10 ± 2 N. A. N. A. > 100
Functional group:
Ureas
5a R=H/ n=2 N. A. 14 ±1 5 N. A. N. A. > 25
5b R=H/ n=3 N. A. 27 ±1 2 15 ±16 3 ± 8 > 100
5c R=H/ n=4 N. A. 16 ± 5 75 ± 12 N. A. > 100
5d R=4-NO2C6H4/ n=2 N. A. . 11 ± 17 37 ± 8 N. A. > 25
5e R=4-NO2C6H4/ n=3 N. A. N. A. 38 ± 6 26 ± 1 > 25
5f R=4-NO2C6H4/ n=4 N. A. 10 ± 10 94 ± 4 N. A. > 10
5g R=CH2Ph/ n=2 N. A. 30 ± 6 5 ± 4 N. A. > 25
5h R=CH2Ph/ n=3 N. A. 16 ± 0 26 ± 6 21 ± 17 > 10
5i R=CH2Ph/ n=4 N. A. 12 ± 12 74 ± 2 5 ± 8 > 10
5j R=(CH2)3CH3/ n=2 N. A. 14 ± 1 18 ± 10 N. A. > 50
5k R=(CH2)3CH3/ n=3 N. A. 17 ± 14 18 ± 3 20 ± 12 > 25
5l R=(CH2)3CH3/ n=4 N. A. 12 ± 12 96 ± 2 81 ± 8 > 10
Functional group:
1,2,3–Triazole
7e n=2 6 ±16 13 ± 2 12 ± 4 6 ±12 > 100
7d n=3 N. A. 11 ± 4 16 ± 6 N. A. > 50
7f n=4 17 ± 2 N. A. 90 ± 3 22 ± 5 > 100
Results show meansactivitiesof at least three independent assays. NOAEL= No-Observed Adverse Effect Level (MTT assay in
PMA-differentiated THP-1 cells);N. A. = no activity.
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